-
2024-519345-30-00
5
2025-11-12
IgA nephropathy
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-518206-40-00
5
2025-11-03
Severe hypertriglyceridemia (SHTG)
-
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
-
2024-515215-21-00
6
2025-10-24
DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF)
-
2025-520698-38-00
9
2025-10-22
Cutaneous Basal Cell Carcinoma
-
2024-517121-10-00
5
2025-10-17
Menstrual Migraine
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-520535-16-00
6
2025-10-10
End-stage renal disease
-
2024-515682-34-00
5
2025-10-06
Chronic migraine
-
2024-515715-22-00
5
2025-10-06
Episodic migraine
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2023-509121-51-00
5
2025-09-30
Moderate-to-Severe Atopic Dermatitis
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-513663-10-01
3
2025-09-17
Neoplasms
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-513171-41-00
5
2025-09-11
Vitiligo
-
2024-520276-10-00
5
2025-09-04
Non-constipated Irritable Bowel Syndrome (IBS)
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-514440-86-00
4
2025-08-04
Relapse/Refractory Large B Cell Lymphoma